Page 19 - Lupin

Nifty Pharma index hits new record high; Laurus Labs, Glenmark Pharma up 3%

Cipla, Cadila Healthcare, Lupin, Sun Pharma and Aurobindo Pharma from the Nifty Pharma index were up in the range of 1 per cent to 2 per cent on the NSE

Nifty is trading in highly overbought zone, avoid fresh long: Sameet Chavan

13,650 is the immediate support which, if breached, could result in some profit booking and drag the index towards 13,500-13,470

Lupin rises on settling dispute with Gavis and Novel; gains 5% in four days

On Wednesday, Lupin announced in a BSE filing that its dispute with the sellers in the Gavis and Novel transaction has been resolved amicably to the satisfaction of all parties.

November domestic pharma sales grow just 1% after strong show last month

Oct growth rate was 9.6%; Most big corporates saw volumes drop in November

Divi's Lab, Aurobindo Pharma: Are pharma stocks losing their sheen? Read on

Till Nifty Pharma holds above the 11,180 mark, the bullish bias will prevail, charts suggest.

USFDA issues 13 observations after inspection of Lupin arm's facility in US

Drug firm Lupin said the US health regulator has issued 13 observations after inspection of its subsidiary's Somerset facility in New Jersey

Lupin: Q2 unimpressive, more triggers required to drive stock

US growth has picked up as anticipated, but India and a few other markets still lag

With US sales recovering, Lupin Q2 profit up 97% over Q1 to Rs 211 cr

The revenues, however, dropped by 1.2 percent on a year on year (YoY) basis to Rs 3,835 crore, but sequentially the revenues rose 8.7 percent

Lupin experiences information security incident, select IT systems affected

Restoration of the impacted systems is a priority and is underway, it added

Lupin shares fall 2% in strong market post September quarter results

In Q2FY21, the company's revenues declined 12 per cent YoY to Rs 3,835 crore mainly due to Kyowa divestment

Rakesh Jhunjhunwala rejigs portfolio in Q2; ups stake in Lupin, Tata Motors

The shareholding pattern disclosed by the Tata group automaker showed Rakesh Jhunjhunwala holding 40 million shares

Pharma stocks gain; Cipla hits record high, Lupin nears 52-week high

In the past month, Cipla and Lupin outperformed the market by gaining 12 per cent each, against 8 per cent rise in Nifty Pharma index

Here's a Bull Spread Strategy on Lupin by Nandish Shah of HDFC Securities

Primary trend of the stock is positive where stock price is trading above its 200-day SMA

Lupin gets USFDA nod to market drug for treating relapsing sclerosis

Lupin said it has received approval from the US health regulator to market generic Dimethyl Fumarate delayed-release capsules used for treatment of relapsing forms of multiple sclerosis in adults

As domestic sales decline, drug makers focus on exports to sustain growth

During April-July, drug makers exported products worth $ 7.4 billion, a growth of 9.5 per cent on year on year basis

Lupin launches generic Divalproex Sodium tablets for bipolar disorder in US

According to IQVIA MAT July 2020 data, Divalproex Sodium extended-release tablets USP had annual sales of approximately USD 130 million (about Rs 950 crore) in the US

BSE Healthcare index hits record high; Laurus Labs, Dr Reddy's at new highs

Lupin, Stride Pharma, Neuland Labs, Lincoln Pharma, and Hikal hit their respective 52-week highs on the BSE

Charts show bulls are making a strong comeback: Nilesh Jain of Anand Rathi

The momentum indicators and oscillators on the weekly scale are very well on buy mode. The volatility index --India VIX -- has also started cooling down which is giving comforts to the bulls

Lupin launches generic rheumatoid arthritis drug 'Leflunomide' in US market

Drug maker Lupin on Wednesday said it has launched Leflunomide tablets, used to treat rheumatoid arthritis, in the US market. The company has launched the product in 10 mg and 20 mg strengths after receiving the approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a statement. The product would be manufactured at drug maker's Pithampur (Unit I) facility in Madhya Pradesh, it added. The Mumbai-based company's product is the generic equivalent of Sanofi-Aventis US LLC's Arava tablets and is indicated for the treatment of adults with active rheumatoid arthritis (RA). As per IQVIA MAT June data, Leflunomide tablets had an annual sales of around USD 42 million in the US.

Launch of inhalation product improves Lupin's revenue visibility

More US launches and uptick in the Indian market are key near-term triggers